Reports Q4 revenue $5.21M, consensus $1.23M. “Our team remains highly focused on achieving our 2026 targets,” said Marc Hedrick, Plus Therapeutics (PSTV) President and Chief Executive Officer. “Specifically, our top priority goals are CNSide commercial scale-up and REYOBIQ pivotal trial readiness; we also are looking aggressively for ways to over achieve where possible.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics: AMA Code Milestone and 2026 Clinical Catalysts Underpin Buy Rating and $1 Target
- Plus announces new Category III CPT code for CED used with Reyobiq
- Is PSTV a Buy, Before Earnings?
- Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses
- Plus Therapeutics initiated with a Buy at Lake Street